echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Express develops breakthrough covalent drugs, Xinrui completes $75 million in Series A financing

    Express develops breakthrough covalent drugs, Xinrui completes $75 million in Series A financing

    • Last Update: 2022-08-12
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Today, Terremoto Biosciences announced the completion of a $75 million Series A financi.


    Advances its covalent platform targeting lysine (Lys)

    Historically, covalent drugs worked by forming covalent bonds with cysteines (Cys) on the surface of protei.


    Cysteine ​​is uncommon in proteins, thus limiting the number of targets that can be targeted by this mechanism

    Terremoto's technology platform aims to expand the types of amino acids that covalent drugs can bind to and develop covalent drugs that target lysine bindi.


    Lysines are widely distributed in the proteome and are present in the drug-action "pockets" of most protei.


    "At Terremoto, we are leveraging covalent chemistry to develop more specific, potent, and superior small-molecule drugs for a range of highly complex and serious diseases," said .


    Original in English: https://

    https://
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.